Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Open Access
- 1 September 2013
- journal article
- review article
- Published by Informa UK Limited in OncoTargets and Therapy
- Vol. 6, 1363-72
- https://doi.org/10.2147/ott.s50208
Abstract
Peer reviewed article authored by (Thon N, Kreth S, Kreth FW). Read article or submit your manuscript for publishing.Keywords
This publication has 99 references indexed in Scilit:
- Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult BrainCell, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspectiveActa Neuropathologica, 2010
- Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiformeJournal of Neuro-Oncology, 2010
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006